Cargando…
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality. Although docetaxel has recently been shown to extend the survival of patients with CRPC in two large randomised phase III studies, subsequent treatment options remain limited for these p...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360544/ https://www.ncbi.nlm.nih.gov/pubmed/16983403 http://dx.doi.org/10.1038/sj.bjc.6603223 |